KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Enterprise Value (2019 - 2025)

Historic Enterprise Value for Royalty Pharma (RPRX) over the last 7 years, with Q4 2025 value amounting to $2.6 billion.

  • Royalty Pharma's Enterprise Value rose 797.09% to $2.6 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $2.6 billion, marking a year-over-year increase of 797.09%. This contributed to the annual value of $2.6 billion for FY2025, which is 797.09% up from last year.
  • Latest data reveals that Royalty Pharma reported Enterprise Value of $2.6 billion as of Q4 2025, which was up 797.09% from $2.3 billion recorded in Q3 2025.
  • Royalty Pharma's 5-year Enterprise Value high stood at $4.2 billion for Q1 2021, and its period low was $1.4 billion during Q2 2023.
  • Over the past 5 years, Royalty Pharma's median Enterprise Value value was $2.5 billion (recorded in 2023), while the average stood at $2.5 billion.
  • Its Enterprise Value has fluctuated over the past 5 years, first skyrocketed by 460354.39% in 2021, then tumbled by 4483.2% in 2022.
  • Royalty Pharma's Enterprise Value (Quarter) stood at $2.9 billion in 2021, then fell by 23.73% to $2.2 billion in 2022, then skyrocketed by 40.15% to $3.1 billion in 2023, then fell by 21.35% to $2.4 billion in 2024, then increased by 7.97% to $2.6 billion in 2025.
  • Its last three reported values are $2.6 billion in Q4 2025, $2.3 billion for Q3 2025, and $2.5 billion during Q2 2025.